All posts tagged: AntiDiabetes

Eli Lilly’s Weight Loss, Anti-Diabetes Drug Mounjaro To Be Launched In 2025

Eli Lilly’s Weight Loss, Anti-Diabetes Drug Mounjaro To Be Launched In 2025

Published by Webster

Last Updated:December 17, 2024, 12:30 IST Not just Tirzepatide, the company plans to launch multiple newly developed products from its global portfolio in the Indian market, including cardiometabolic health, oncology, immunology and neuroscience Mounjaro, a weekly injectable drug by Eli Lilly for treating type 2 diabetes and obesity, competes with another high-profile drug, Ozempic. (Representational pic) Eli Lilly, a US-based pharmaceutical giant, plans to launch its drug, Tirzepatide, sold under the brand name Mounjaro, in the Indian market next year. Mounjaro, a weekly injectable drug by Eli Lilly for treating type 2 diabetes and obesity, competes with another high-profile drug, Ozempic (manufactured by Danish drugmaker, Novo Nordisk). The latter, brand name Ozempic (semaglutide), has not yet been launched in the Indian market. “We aim to launch Tirzepatide in India by 2025, after obtaining all necessary regulatory approvals,” Vineet Gupta, associate vice president and managing director of Eli Lilly (India), told News18. However, he said that the company hasn’t yet “finalised the pricing of Tirzepatide for India”. Gupta did not reveal its pricing strategy for the …

Pan D, Shelcal, Anti-Diabetes & High BP Drugs Fail Quality Tests at Govt Labs, Makers Blame Spurious Batches

Published by Webster

Antacid Pan D, calcium supplement Shelcal, anti-diabetic drug Glimepiride, high blood pressure drug Telmisartan and many more top-selling medicines have been flagged for failing quality tests in the latest monthly drug alert issued by the country’s drug regulatory agency. According to the “Not of Standard Quality (NSQ) alert” for August, released by the country’s drug regulation watchdog Central Drugs Standards Control Organisation (CDSCO), more than 50 drugs have been declared NSQ or substandard. NSQ alerts are results of random sampling done by state drug officers on a monthly basis. The list holds importance due to the failure of critical, essential medicines manufactured by several top pharma firms, including Hetero Drugs, Alkem Laboratories, Hindustan Antibiotics Limited (HAL) and Karnataka Antibiotics & Pharmaceuticals Ltd. The companies, however, have indicated that the flagged batches are spurious and not manufactured by them. Popular drugs failing quality tests Multiple batches of the well-known hypertension drug Telmisartan have failed quality tests. These drugs were manufactured by Haridwar-based drugmaker Life Max Cancer Laboratories. A popular drug to treat stomach infections, Metronidazole, manufactured …